Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 5/20 | 0.32 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24247669 | 0.93 | EPHX1 (0.51) | EPHX1CES1FAAHCES2 | |
| SCHEMBL6462728 | 0.89 | CA1 (0.43) | EPHX1CA1CA12CA7CA14 | |
| SCHEMBL29615765 | 0.81 | EPHX1 (0.48) | EPHX1CA1CA12CA7CA14 | |
| SCHEMBL6460339 | 0.80 | EPHX1 (0.38) | EPHX1CA1CA2HTT | |
| SCHEMBL28489251 | 0.79 | EPHX1 (0.37) | EPHX1CA1CA2 | |
| SCHEMBL28489693 | 0.79 | EPHX1 (0.37) | EPHX1CA1CA2 | |
| SCHEMBL28497015 | 0.79 | EPHX1 (0.37) | EPHX1CA1CA2 | |
| Pentane SCHEMBL29587231 | 0.78 | EPHX1 (0.57) | EPHX1CA1CA12CA7CA14 | |
| SCHEMBL29687148 | 0.77 | EPHX1 (0.42) | EPHX1CA1CA12CA2 | |
| SCHEMBL12173295 | 0.77 | ALDH1A1 (0.41) | EPHX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074668-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2005-04-07 | — | — | US | disclosed |
| US-20030052310-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-0850920-B1 | Ionic conductive materials comprising salts of perfluorinated amides and uses thereof | CENTRE NAT RECH SCIENT (FR) | 2002-09-11 | — | — | EP | disclosed |
| US-20020009650-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6319428-B1 | Perfluorinated amide salts and their uses as ionic conducting materials | HYDRO-QUEBEC (CA) | 2001-11-20 | — | — | US | disclosed |
| WO-1998029388-A1 | PERFLUORINATED AMIDE SALTS AND THEIR USES AS IONIC CONDUCTING MATERIALS | HYDRO-QUEBEC (CA) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020009650-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | AFF4, NHERF1, AFF2 | EPHX1 2411/4885CA1 860/4885CA12 1237/4885 |
| US-20050074668-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | AFF4, AFF2, AFF1 | EPHX1 1801/4885CA1 689/4885CA12 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.